USFDA approved Zydus for baclofen tablets

The US Food and Drug Administration (FDA) approved Zydus Cadila to market baclofen tablets, 5 mg.

Baclofen is used to treat muscle spasms caused by certain conditions like multiple sclerosis, spinal cord injury/disease. Baclofen helps in relaxing the muscles. It will be manufactured at the group’s formulations manufacturing facility at Baddi.

  • Related Posts

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Dr Rajendra Pratap Gupta gets nominated to advise UN Secretary General Geneva/ New Delhi: Former advisor to Union Health Minister of India JP Nadda in his earlier stint and a…

    IPC releases draft NFI-2026 to promote rational use of medicines

    Ghaziabad:- The Indian Pharmacopoeia Commission (IPC) has taken a significant step toward strengthening public health systems with the draft release of the National Formulary of India (NFI) 2026, a comprehensive…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

    Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

    FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

    FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    Pvt nursing home sealed in Chatra after woman, unborn baby die

    Pvt nursing home sealed in Chatra after woman, unborn baby die

    30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

    30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

    Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

    Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy